The drug was being tested in combination with chemo and an interim analysis apparently showed no survival benefit was likely:http://www.masshightech.com/stories/2010/11/08/daily47-Novartis-halts-lung-cancer-trial.htmlThat makes the NSCLC space a little less crowded for 011.
Bloomberg has article today on UK National Health Centre for Excellence rejection of Roche's Avastin in use with chemo in colorectal cancer...price was going to be 33k for the year.
According to this article Avastin extends life in colorectal patients by an average of only 6 weeks:http://www.bbc.co.uk/news/health-11736595That's not much even by cancer drug standards. I can see why the UK health service had a problem with it.
I see from reading Novartis' PR that this was a second-line trial. Novartis apparently announced in March that the same agent also failed a first-line NSCLC trial:http://www.novartis.com/newsroom/media-releases/en/2010/1461276.shtmlSince OGXI and Teva presumably intend the 011 P3 trial to be in the first-line setting, Novartis' March PR was probably more relevant to OGXI than the one they issued yesterday.